Download PDF
Zentralbl Gynakol 2002; 124(7): 356-361
DOI: 10.1055/s-2002-35534
Übersichten

© Georg Thieme Verlag Stuttgart · New York

Aktuelle Aspekte des Endometriumkarzinoms[*]

Actual Aspects of Endometrial CarcinomaJ. Dietl
  • Universitäts-Frauenklinik Würzburg
Further Information

Publication History

Publication Date:
19 November 2002 (online)

   Buy Article Permissions and Reprints

Zusammenfassung

Mittlerweile ist das Endometriumkarzinom das häufigste Malignom der weiblichen Genitalien. Pathogenetisch lassen sich 2 Typen unterscheiden: der klassische östrogeninduzierte endometriale und der nichtklassische hormonunabhängige seröse Typ. Die adenomatöse Hyperplasie als Präkanzerose zu identifizieren, ist bisher in hohem Maße an subjektive Kriterien gebunden und dementsprechend wenig reproduzierbar. Eine Verbesserung mittels morphometrischer und molekulargenetischer Methoden erscheint hilfreich. Für die Diagnose des Endometriumkarzinoms ist nach wie vor die fraktionierte Kürettage der Goldstandard. Die Differenzialdiagnose zwischen einem Adenokarzinom des Endometriums und der Endozervix lässt sich durch eine Kombination von Antikörpern immunhistochemisch abklären. Der Eckpfeiler der Therapie ist die Operation, wobei eine differenzierte individuelle Entscheidung je nach histologischem Befund bedeutsam ist. Zunehmend umstritten ist die postoperative adjuvante Radiatio, während die Brachytherapie der Vagina mittlerweile als etabliert gilt. Der vorliegende Artikel vermittelt einen Überblick über die aktuelle Situation der Pathogenese, Diagnose und Therapie des Endometriumkarzinoms.

Abstract

The endometrial carcinoma is meanwhile the most common malignant tumor of the female genital tract. 2 subtypes can be divided according the pathogenesis: the classical estrogen related endometroid type and the nonclassical estrogen unrelated serous type. The endometrial adenomatous hyperplasia as a precancerous lesion must be identified by subjective criteria. Therefore the histological diagnosis is worse reproducible. An improvement would be helpful by morphometric and moleculargenetic methods. The golden standard of diagnosis of the endometrial carcinoma is fractional dilatation and curettage. Immunohistochemical staining with a limited panel of antibodies can discriminate between an endometrial and an endocervical origin of an adenocarcinoma. The corner stone of the therapy is surgery. An individual decision about postoperative treatment is very important and depends on histological criteria. The adjuvant postoperative whole pelvic radiation is under discussion whereas the vaginal brachytherapy is established as standard therapy. This article outlines an overview of the actual situation for pathogenesis, diagnosis and treatment endometrial cancer.

Schlüsselwörter

Endometriumkarzinom - Pathogenese - Diagnose - Therapie

Keywords

Endometrial carcinoma - pathogenesis - diagnosis - therapy

1 Auszugsweise vorgetragen am 23. 02. 2002 anlässlich „Gynäkologie und Geburtshilfe, Frankfurt, 2002”

Literatur

  • 1 Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients.  Obstet Gynecol. 1980;  56 419-427
    PubMedGoogle Scholar
  • 2 Arikan G, Reich O, Weiss U, Hahn T, Reinisch S, Tamussino K, Pickel M, Desoye G. Are endometrial carcinoma cells disseminated at hysteroscopy functionally viable?.  Gynecol Oncol. 2002;  83 221-226
    PubMedGoogle Scholar
  • 3 Ben-Yehuda O M, Kim Y B, Lendter R S. Does hysteroscopy improve on the sensitivity of dilatation and curettage in the diagnosis of endometrial hyperplasia or carcinoma?.  Gynecol Oncol. 1998;  68 4-7
    CrossrefPubMedGoogle Scholar
  • 4 Bergeron C, Nogades F F, Masseroli M, Abeler V, Duvillard P, Müller-Holzner E, Pichartz H, Wells M. A multicentric European study testing the reproducibility of the WHO classification of endometrial hyperplasia with a proposal of a simplified working classification of biopsy and curettage specimens.  Am J Surg Pathol. 1999;  23 1102-1108
    CrossrefPubMedGoogle Scholar
  • 5 Boente M P, Yordan E L, McIntosh D G, Grendys E C, Orandi Y A, Davies S, Beck D, Graham J E, Miller A, Marshall R, Dolan T, Kirschner C, Reddy S, Wilbanks G D. Prognostic factors and long-term survival in endometrial adenocarcinoma with cervical involvement.  Gynecol Oncol. 1993;  51 316-322
    CrossrefPubMedGoogle Scholar
  • 6 Boente M P, Orandi Y A, Yordan E L, Miller A, Graham J E, Kirshner C, Wilbanks G D. Recurrence patterns and complications in endometrial adenocarcinoma with cervical involvement.  Am Surg Oncol. 1995;  2 138-144
    PubMedGoogle Scholar
  • 7 Bokhman J V. Two pathogenetic types of endometrial carcinoma.  Gynecol Oncol. 1983;  15 10-17
    CrossrefPubMedGoogle Scholar
  • 8 Boronow R. Surgical staging of endometrial cancer: evolution, evaluation and responsible challenge - a personal perspective.  Gynecol Oncol. 1997;  66 179-189
    CrossrefPubMedGoogle Scholar
  • 9 Castrillon D H, Lee K R, Nucci M R. Distinction between endometrial and endocervical adenocarcinoma: an immunohistological study.  Int J Gynecol Pathol. 2002;  21 4-10
    PubMedGoogle Scholar
  • 10 Cheng W, Lin H, Toung P, Huang S. Comparison of endometrial changes among symptomatic Tamoxifen-treated and nontreated perimenopausal and postmenopausal breast cancer patients.  Gynecol Oncol. 1997;  66 233-237
    CrossrefPubMedGoogle Scholar
  • 11 Cornelison T L, Trimble E L, Kosary C L. SEER data, corpus uteri cancer: treatment trends versus survival for FIGO stage II; 1988-1994.  Gynecol Oncol. 1999;  74 350-355
    CrossrefPubMedGoogle Scholar
  • 12 Creasman W T, De Geest K, Di Saia P J, Zaino P J. Significance of true surgical pathology staging: a Gynecologic Group study.  Am J Obstet Gynecol. 1999;  181 31-34
    PubMedGoogle Scholar
  • 13 Creutzberg L L, van Putten W L, Koper P, Lybeert M J, Jobsen J, Warlam-Rodenhuis C C, de Winter K A, Lutgens L C, van-den Bergh L, van de Steen-Banasik E, Beerman H, van Lent M. Surgery and post-operative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomized trial.  Lancet. 2000;  355 1404-1411
    CrossrefPubMedGoogle Scholar
  • 14 Dallenbach-Hellweg G, Schmidt D. Distinction between endometrial and endocervical adenocarcinoma.  Int J Gynecol Pathol. 2002;  21 307-308
    PubMedGoogle Scholar
  • 15 Dietl J. Das Lymphknotenproblem in der Frauenheilkunde.  Geburtsh Frauenheilk. 1999;  59 589-598
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Dietl J, Stoll P. Zur Effizienz der Früherkennung des Endometriumkarzinoms durch die endouterine Zellentnahme mit der Mi-Mark-Spirale.  Geburtsh Frauenheilk. 1985;  45 299-301
    PubMedGoogle Scholar
  • 17 Duska L R, Garrett A, Rueda B R, Haas J, Chang Y, Fuller A F. Endometrial cancer in women 40 years old and younger.  Gynecol Oncol. 2001;  83 388-393
    CrossrefPubMedGoogle Scholar
  • 18 Egarter C, Krestan C, Kurz C. Abdominal dissemination of malignant cells with hysteroscopy.  Gynecol Oncol. 1996;  63 143-144
    CrossrefPubMedGoogle Scholar
  • 19 Ellenson L H. II. the molecular biology of endometrial tumorigenesis : does it have a message?.  Int J Gynecol Pathol. 2000;  19 310-313
    PubMedGoogle Scholar
  • 20 Eltabbakh G H, Moore A D. Survival of women with surgical stage II endometrial cancer.  Gynecol Oncol. 1999;  74 80-85
    CrossrefPubMedGoogle Scholar
  • 21 Evans-Metcalf E R, Brooks S E, Reale F R, Baker S P. Profile of women 45 years of age and younger with endometrial cancer.  Obstet Gynecol. 1998;  91 349-354
    CrossrefPubMedGoogle Scholar
  • 22 Fanning J. Long term survival of intermediate risk endometrial cancer (stage I G2, Ic, II) treated with full lymphadenectomy and brachytherapy without teletherapy.  Gynecol Oncol. 2001;  82 371-374
    CrossrefPubMedGoogle Scholar
  • 23 Fanning J, Nanavati P J, Hilgers R D. Surgical staging and high dose rate brachytherapy for endometrial cancer: limiting radiotherapy of node-positive tumors.  Obstet Gynecol. 1996;  87 1041-1044
    CrossrefPubMedGoogle Scholar
  • 24 Feldman S, Clapter A, Welch W, Berkowitz R S. The year follow-up of 263 patients with post/perimenopausal women vaginal bleeding and negative initial biopsy.  Gynecol Oncol. 1994;  55 56-59
    CrossrefPubMedGoogle Scholar
  • 25 Feltmate C M, Duska L R, Chang Y, Flynn C E, Nikrini N, Kiggunden E, Goodman A, Fuller A F, McIntyre J E. Predictors of recurrence in surgical stage II endometrial adenocarcinoma.  Gynecol Oncol. 1999;  73 407-411
    CrossrefPubMedGoogle Scholar
  • 26 Gibson L E, Barakat R R, Ven Katraman E S, Hoskins W J. Endometrial pathology at dilatation and curettage in breast cancer patients: comparison of Tamoxifen users and nonusers.  Cancer J Sci Am. 1996;  2 35-38
    PubMedGoogle Scholar
  • 27 Gitsch G, Hanzal E, Jenson D, Hacker N F. Endometrial cancer in premenopausal women 45 years and younger.  Obstet Gynecol. 1995;  85 504-508
    CrossrefPubMedGoogle Scholar
  • 28 Grimes D A. Diagnostic dilatation and curettage: a reappraisal.  Am J Obstet Gynecol. 1982;  142 1-6
    PubMedGoogle Scholar
  • 29 Gucer F, Tamussino K, Moser F, Arikan G, Winter R. Two-year follow-up of patients with endometrial carcinoma after preoperative fluid hysteroscopy.  Int J Gynecol Cancer. 1998;  8 476-480
    CrossrefPubMedGoogle Scholar
  • 30 Guido R S, Kanbour-Shakir A, Rubin M C, Christopherson W A. Pipelle endometrial sampling: sensitivity in the detection of endometrial cancer.  J Reprod Med. 1995;  40 553-555
    PubMedGoogle Scholar
  • 31 Haenggi W, Gasser A, Feyereisl J, Maibach R, Spoerri S, Greiner R, Dreher E. Curative treatment of clinical stage II endometrial carcinoma.  Zentralbl Gynäkol. 1995;  117 207-212
    PubMedGoogle Scholar
  • 32 Horowitz N S, Petus W A, Smith M M, Drescher C W, Atwood M, Mate T. Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial carcinoma.  Obstet Gynecol. 2002;  99 235-240
    CrossrefPubMedGoogle Scholar
  • 33 Kamoi S, AlJuboury M I, Akin M-R, Silverberg S G. Immunohistochemical staining in the distinction between primary endometrial and endocervical adenocarcinomas: another viewpoint.  Int J Gynecol Pathol. 2002;  21 217-223
    PubMedGoogle Scholar
  • 34 Karlsson B, Crauberg S, Wickland M, Ylöstalo P, Torvid K, Marsal K, Valentin L. Transvaginal ultrasonography of the Endometrium in women with postmenopausal bleeding - a Nordic multicenter study.  Am J Obstet Gynecol. 1995;  172 1488-1494
    CrossrefPubMedGoogle Scholar
  • 35 Kendall B S, Ronnett B M, Isaeson C, Cho K R, Hedrick L, Diener-West M, Kurman R J. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma.  Am J Surg Pathol. 1998;  22 1012-1019
    CrossrefPubMedGoogle Scholar
  • 36 Kim Y B, Holschneider C H, Ghosh K, Nieberg R K, Montz F J. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature.  Cancer. 1997;  79 320-327
    CrossrefPubMedGoogle Scholar
  • 37 Kimmig R, Strowitzki T, Müller-Hocker J, Kürzl R, Korell M, Hepp H. Conservative treatment of endometrial cancer permitting subsequent triplet pregnancy.  Gynecol Oncol. 1995;  58 255-257
    CrossrefPubMedGoogle Scholar
  • 38 Krauß T, Huschmand H, Hinney B, Viereck V, Emons G. Hormon- und Chemotherapie beim Endometriumkarzinom.  Zentralbl Gynaekol. 2002;  124 45-50
    Article in Thieme ConnectPubMedGoogle Scholar
  • 39 Kurman R J. Introduction to the ISGYP symposium on endometrial hyperplasia.  Int J Gynecol Pathol. 2000;  19 299-300
    PubMedGoogle Scholar
  • 40 Larson D M, Broste S K, Krawisz B R. Surgery without radiotherapy for primary treatment of endometrial Cancer.  Obstet Gynecol. 1998;  91 355-359
    CrossrefPubMedGoogle Scholar
  • 41 Lax S F. Molekulare Pathogenese des Endometriumkarzinoms auf Basis eines dualistischen Modells.  Zentralbl Gynäkol. 2002;  124 10-16
    PubMedGoogle Scholar
  • 42 Le T D, Yamada S D, Rutgers J L, Di Saia P J. Complete response of a stage IV uterine papillary serous carcinoma to neoadjuvant chemotherapy with Taxol and carboplatin.  Gynecol Oncol. 1999;  73 461-463
    CrossrefPubMedGoogle Scholar
  • 43 Lybeert M L, van Putten W L, Brolmann H A, Coebergh J W. Postoperative radiotherapy for endometrial carcinoma stage I. Wide variation in referral patterns but no effect on long-term survival in a retrospective study in the southeast Netherlands.  Eur J Cancer. 1998;  34 586-590
    CrossrefPubMedGoogle Scholar
  • 44 Mariani A, Webb M J, Keeney G L, Calori G, Podratz K C. Role of wide/ radical hysterectomy and pelvic lymph node dissection in endometrial cancer with cervical involvement.  Gynecol Oncol. 2001;  83 72-80
    CrossrefPubMedGoogle Scholar
  • 45 Mc Cluggage W G, Sumathi V P, Mc Bride H A, Patterson A. A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptors, aids the distinction between primary endometrial and endocervical adenocarcinomas.  Int J Gynecol Pathol. 2002;  21 11-15
    PubMedGoogle Scholar
  • 46 Macdonald R R, Thorogood J, Mason M K. A randomized trial of progestogens in the primary treatment of endometrial carcinoma.  Br J Obstet Gynaecol. 1988;  95 166-174
    PubMedGoogle Scholar
  • 47 Morrow C P, Bundy B N, Homesley H D, Creasman W T, Hornback N B, Kurman R, Thigpen J T. Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynaecologic Oncology Group Study.  Gynecol Oncol. 1990;  36 166-171
    CrossrefPubMedGoogle Scholar
  • 48 Morrow C P, Bundy B N, Kurman R J, Creasman W T, Heller P, Homesley H D, Graham J E. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the Endometrium: a Gynecologic Oncology Group study.  Gynecol Oncol. 1991;  40 55-65
    CrossrefPubMedGoogle Scholar
  • 49 Mutter G L. Histopathology of genetically defined endometrial precancers.  Int J Gynecol Pathol. 2000;  19 301-309
    PubMedGoogle Scholar
  • 50 Mutter G L. Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group.  Gynecol Oncol. 2000;  76 287-290
    CrossrefPubMedGoogle Scholar
  • 51 Ng T J, Nicklin J L, Perrin L C, Chenk R, Crandon A J. Postoperative vaginal vault brachytherapy for node-negative stage II (occult) endometrial carcinoma.  Gynecol Oncol. 2001;  81 193-195
    CrossrefPubMedGoogle Scholar
  • 52 Ng T Y, Perrin L C, Nicklin J L, Chenk R, Crandon A J. Local recurrence in high-risk node-negative stage I endometrial carcinoma treated with postoperative vaginal vault brachytherapy.  Gynecol Oncol. 2000;  79 490-494
    CrossrefPubMedGoogle Scholar
  • 53 Orr J W. Surgical staging of endometrial cancer: does the patient benefit?.  Gynecol Oncol. 1998;  71 335-339
    CrossrefPubMedGoogle Scholar
  • 54 Orr J W, Holimon J L, Orr P F. Stage I corpus cancer: Is teletherapy necessary?.  Am J Obstet Gynecol. 1997;  176 777-789
    PubMedGoogle Scholar
  • 55 Pecorelli S. FIGO Annual report on the result of treatment in gynaecological cancer, 23rd ed.  J Epidemiol Biostat. 1998;  3 1-168
    PubMedGoogle Scholar
  • 56 Podratz K C, Mariani A, Webb M J. Staging and therapeutic value of lymphadenectomy in endometrial cancer.  Gynecol Oncol. 1998;  70 163-164
    CrossrefPubMedGoogle Scholar
  • 57 Randall T C, Kurman R J. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40.  Obstet Gynecol. 1997;  90 434-440
    CrossrefPubMedGoogle Scholar
  • 58 Roberts J A, Brunetto V L, Keys H M, Zaino R, Spiritos N M, Blass J D, Pearlman A, Mainan M A, Bell J G. A phase III randomized study of surgery vs surgery plus adjunctive radiation therapy in intermediate-risk endometrial adenocarcinoma.  Proc Soc Gynecol Oncol. 1998;  29 70
    PubMedGoogle Scholar
  • 59 Rogerson L, Downes E. How do UK gynaecologists manage endometrial carcinoma? A national survey.  Eur J Gynaecol Oncol. 1998;  19 331-332
    PubMedGoogle Scholar
  • 60 Rose P G. Endometrial carcinoma.  N Engl J Med. 1996;  335 640-649
    CrossrefPubMedGoogle Scholar
  • 61 Salvesen H B, Stefansson I, Kalvenes M B, Das S, Akslen L A. Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma.  Cancer. 2002;  94 2185-2191
    CrossrefPubMedGoogle Scholar
  • 62 Schmidt D, Horn L-C. Präkanzeröse Läsionen des Endometriums und Veränderungen unter Tamoxifen-Therapie.  Zentralbl Gynäkol. 2002;  124 3-9
    PubMedGoogle Scholar
  • 63 Schmidt T, Römer Th. Sonographie und Hysteroskopie beim Endometriumkarzinom und seinen Vorstufen.  Zentralbl Gynäkol. 2002;  124 20-26
    PubMedGoogle Scholar
  • 64 Scully R E, Bonfiglio T A, Kurman R J, Silverberg S G, Wilkinson E J. WHO-International Histological Classification of Tumours. Histological Typing of Female Genital Tract Tumours. 2nd ed. Springer-Verlag, New York 1994
    Google Scholar
  • 65 Seago P D, Raman A, Shashikant L. Potential benefit of lymphadenectomy for the treatment of node-negative locally advanced uterine cancers.  Gynecol Oncol. 2001;  83 282-285
    CrossrefPubMedGoogle Scholar
  • 66 Sherman M E. Theories of endometrial carcinogenesis: a multidisciplinary approach.  Mod Pathol. 2000;  13 295-308
    CrossrefPubMedGoogle Scholar
  • 67 Stovall T G, Ling F W, Morgan P L. A prospective, randomised comparison of the Pipelle endometrial sampling device with the Novak curette.  Am J Obstet Gynecol. 1991;  165 1287-1290
    PubMedGoogle Scholar
  • 68 Straughn M J, Huch W K, Kelly F J, Leath C A, Kleinberg M J, Hyde J, Numnum T M, Zhang Y, Soong S-J, Austin J M, Patridge E E, Kilgore Ö C, Alvarez R D. Conservative management of stage I endometrial carcinoma after surgical staging.  Gynecol Oncol. 2002;  84 194-200
    CrossrefPubMedGoogle Scholar
  • 69 Townsend D E, Fields G, Mc Camland A, Lauffman K. Diagnostic and operative hysteroscopy in the management of persistent postmenopausal bleeding.  Obstet Gynecol. 1993;  82 419-424
    PubMedGoogle Scholar
  • 70 Vergote J, Kjorstad K, Abeler V, Kolstad P. A randomized trial of adjuvant progestagen in early endometrial cancer.  Cancer. 1989;  64 1011-1016
    PubMedGoogle Scholar
  • 71 Volker P, Grundker C, Schmidt O, Schulz K D, Emons G. Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity hormone releasing hormone analogues.  Am J Obstet Gynecol. 2002;  186 171-179
    CrossrefPubMedGoogle Scholar
  • 72 Wang C-B, Wang C-J, Huang H-J, Hsueh S, Chou H-H, Soong Y-K, Lai C-H. Fertility-Preserving treatment in young patients with endometrial adenocarcinoma.  Cancer. 2002;  94 2192-2198
    CrossrefPubMedGoogle Scholar
  • 73 Yura Y, Tauchi K, Koshiyama M, Konishi J, Yura S, Mori T, Matasushita K, Hayashi M, Yoshida M. Parametrial involvement in endometrial carcinomas: its incidence and correlation with other histological parameters.  Gynecol Oncol. 1996;  63 114-119
    CrossrefPubMedGoogle Scholar
  • 74 Zaino R J. III. Endometrial hyperplasia: is it time for a quantum leap to a new classification?.  Int J Gynecol Pathol. 2000;  19 314-321
    PubMedGoogle Scholar
  • 75 Zaino R J, Hershey M S. The fruits of our labours: distinguishing endometrial from endocervical adenocarcinoma.  Int J Gynecol Pathol. 2002;  21 1-3
    PubMedGoogle Scholar
  • 76 Zanetta G, Gabriele A, Losa G, Capellini A, Mangioni C. Conservative management of endometrial carcinoma with prolonged preservation of the uterus in a young patient.  Int J Gynecol Cancer. 1997;  7 332-334
    CrossrefPubMedGoogle Scholar
  • 77 Zanotti K M, Belinson J L, Kennedy A W, Webster K D, Marckman M. The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma.  Gynecol Oncol. 1999;  74 272-277
    CrossrefPubMedGoogle Scholar

1 Auszugsweise vorgetragen am 23. 02. 2002 anlässlich „Gynäkologie und Geburtshilfe, Frankfurt, 2002”

Prof. Dr. med. Johannes Dietl

Universitäts-Frauenklinik

Josef-Schneider-Str. 4

97080 Würzburg

Phone: 09 31/2 01/2 52 50

Fax: 09 31/2 01/2 54 06

Email: j.dietl@mail.uni-wuerzburg.de

      >